

Merus

Merus to Present at Canaccord Genuity's 44th Annual Growth Conference

August 6, 2024 at 8:00 AM EDT

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- [Merus N.V.](#) (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclomics® and Triclomics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Canaccord Genuity's 44th Annual Growth Conference on Tuesday, August 13, 2024 from 9:00-9:25 a.m. ET.

The webcast of the presentation will be contemporaneously available on the [investors page](#) of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus

[Merus](#) is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as [Multiclomics®](#). Multiclomics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit [Merus' website](#), [X](#) and [LinkedIn](#).

Multiclomics®, Biclomics® and Triclomics® are registered trademarks of Merus N.V.

Investor and Media Inquiries:

Sherri Spear

Merus N.V.

SVP Investor Relations and Strategic Communications

617-821-3246

s.spear@merus.nl

Kathleen Farren

Merus N.V.

Assoc. Director IR/Corp Comms

617-230-4165

k.farren@merus.nl

Merus